Results from the national Myeloma X trial, published online in The Lancet Oncology, have shown that a second high-dose therapy and autologous stem cell transplant (HDT-ASCT) is more effective than cyclophosphamide in myeloma patients who have relapsed following initial HDT-ASCT. The authors indicated that the evidence would likely have an impact on clinical practice and provide a further treatment option for patients at first relapse.

Read the full article ยป